学术会议:紧随研究趋势 洞察学术热点 进入>
产业会议:新技术,新领域,深入产业环节 进入>
举办会议及论坛超过百场 邀请海内外院士超过50名 教授PI专家授课超过1000名 总参会人数超过10万人
2017-11-02至2017-11-03 中国上海
Menu
报名参会
Sign up

大会主席CongressChairman

丁健 院士

中科院上海药物研究所

丁健 院士

中科院上海药物研究所

简历:

教育经历

1975.11-1978.11 江西医学院 本科

1980.09-1983.09 中国医科大学 硕士

1986.10-1991.03 日本国立九州大学 博士

工作经历

1986.10-1992.1 日本国立九州大学 博士生、访问学者

1992.2-1994.2 中国科学院上海药物研究所 博士后

1994.2-现在 中国科学院上海药物研究所 课题组组长/研究员

1996.8-2004.11 中国科学院上海药物研究所 副所长/研究员

2001.1-2003.1 国家新药筛选中心 主任/研究员

2005.1-2012.1 新药研究国家重点实验室 主任/研究员

2005.12-2013.12 中国科学院上海药物研究所 所长

研究方向:

1.分子靶向抗肿瘤药物的研发,主要关注靶点涉及多个领域:

  1)受体酪氨酸激酶;

  2PI3K/mTOR信号通路;

  3)肿瘤表观遗传修饰调控酶;

  4)肿瘤新生血管生成调控因子。 

2.抗肿瘤药物作用机制研究:

  1)肿瘤细胞信号转导通路;

  2)肿瘤分子生物标志物;

  3)抗肿瘤转移。

代表论著:

1. Ai J, Tang QJ, Wu YL, Xu Y, Feng T, Zhou RY, Chen Y, Gao X, Zhu QF, Yue XH, Pan QN, Xu SY, Li J, Huang M, Daugherty-Holtrop J, He YZ, Xu HE, Fan J*, Ding J*, Geng M*. The Role of Polymeric Immunoglobulin Receptor in Inflammation-Induced Tumor Metastasis of Human Hepatocellular Carcinoma. J Natl Cancer Inst. 103:1696-712, 2011

 

2. Jiang Y., Miao ZH*., Xu L., Yu B., Gong JX., Tong LJ., Chen Y., Zhou ZL., Liu HC., Wang Y., Guo YW., Ding J*. Drug transporter-independentliver cancer cell killing by marine steroid methyl spongoate via intrinsic and extrinsic apoptosis pathways. J BiolChem 286:26461-9, 2011

 

3. Zhang J, Xin X, Chen Q, Xie Z, Gui M, Chen Y, Lin L, Feng J, Li Q, Ding J*, Geng M*. Oligomannurarate sulfate sensitizes cancer cells to doxorubicin by inhibiting atypical activation of NF-κB via targeting of Mre11. Int J Cancer. 130: 467477, 2012

 

4. Chen G, Chen SM, Wang X, Ding XF, Ding J*, Meng LH*. Inhibition of Chemokine (CXC Motif) Ligand 12/Chemokine (CXC Motif) Receptor 4 Axis CXCL12/CXCR4)-mediated Cell Migration by Targeting Mammalian Target of Rapamycin (mTOR) Pathway in Human Gastric Carcinoma Cells. J Biol Chem. 287(15):12132-41, 2012 .

 

5. Chen SM, Liu JL, Wang X, Liang C, Ding J*, Meng LH*. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR. BiochemPharmacol. 83(9):1183-94, 2012.

 

6. Yu B, Li MH, Wang W, Wang YQ, Jiang Y, Yang SP, Yue JM, Ding J*, Miao ZH*. Pseudolaric acid B-driven phosphorylation of c-Jun impairs its role in stabilizing HIF-1alpha: a novel function-converter model. J Mol Med (Berl). 90(8):971-81,2012.

 

7. Zhou Y, Chen Y, Tong L, Xie H, Wen W, Zhang J, Xi Y, Shen Y, Geng M, Wang Y, Jiang H, Luo C, Lin L*, Ding J*. AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and antitumor activity via targeting VEGFR, FGFR, and PDGFR. J Cell Mol Med. 16(10):2321-2330, 2012.

 

8. Zhu CH., Chen Q., XieZQ., Ai J., Tong LJ., Ding J*., Geng MY*. The role of histone deacetylase 7 (HDAC 7) in cancer cell proliferation: regulation on c-Myc. J Mol Med 89: 279-89, 2011

 

9. Zhang ZX., Meng T., Yang N., Wang W., Xiong B., Chen Y., Ma LP., Shen JK., Miao ZH*, Ding J*. MT119, a new planar-structured compound, targets the colchicine site of tubulin arresting mitosis and inhibiting tumor cell proliferation. Inter J Cancer 129: 214-24, 2011.

 

10. Chen G, Yang N, Wang X, Zheng SY, Chen Y, Tong LJ, LI YX, Meng L*., Ding J*.Identification of p27/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer. J Mol Med 88: 941-52, 2010

 

11. Li M, Miao ZH, Chen Z, Chen Q, Gui M, Lin LP, Sun P, Yi YH, Ding J*. Echinoside A, a new marine-derived anticancer saponin, targets topoisomerase II? by unique interference with its DNA binding and catalytic cycle. Ann Oncol 21: 597-607, 2010.

 

12. Li T, Wang J, Wang X, Yang N, Chen SM, Tong LJ, Yang CH, Meng LH, Ding J*. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant. J PharmacolExpTher. 334:830-8, 2010

 

13. Lu JJ.,Meng LH*., Shankavaramb UT., Zhu CH., Tong LJ., Chen G., Lin LP., Weinsteinc JN., Ding J*. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. BiochemPharmacol 80: 22-30, 2010.

 

14. Yu B, Miao ZH, Jiang Y, Li MH, Yang N, Li T, Ding J*. c-Jun Protects Hypoxia-Inducible Factor-1{alpha} from Degradation via Its Oxygen-Dependent Degradation Domain in a Nontranscriptional Manner. Cancer Res. 69:7704-12, 2009

 

15. Li Z, Zhou ZL, Miao ZH, Lin LP, Feng HJ, Tong LJ, Ding J*, Li YC*. Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents. J Med Chem. 52:5115-23, 2009

 

16. Zhu H, Miao ZH*, Huang M, Feng JM, Zhang ZX, Lu JJ, Cai YJ, Tong LJ, Xu YF, Qian XH, Ding J*. Naphthalimides induce G2 phase arrest in HCT-116 cells via ATM-activated Chk2-executed pathway. Neoplasia 11: 122634. 2009

 

17. Zhang C, Yang N, Yang CH, Ding HS, Luo C, Zhang Y, Wu MJ, Zhang XW, Shen X, Jiang HL, Meng LH, Ding J*. S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton. PLoS One. 2009;4(3):e4881.

 

18. Ren X, Dai M, Lin LP, Li PK, Ding J*. Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent. Br J Pharmacol. 156 :1228-38, 2009.


邀请函

下载邀请函

赞助企业

大会咨询
姓名 *

E-mail*

电话: *

消息: *

×
留下姓名电话和邮箱,邀请函直接发送到邮箱
*姓名:
* 电话:
* Email: